B2B only. For licensed importers and distributors. Tender authorities and healthcare institutions are also served. Not for retail or patient supply.  ·  Compliance statement
Home/Insights/Registration
Regulatory framework

NMPA registration requirements: what a drug needs to be approved in China

To register a drug in China you have to prove three things — safety, efficacy and controllable quality — and you prove them with data, not with a form. The class you register under decides how much data, and a biological product is always the heavier lift.

Chinese drug registration is governed by the Drug Registration Regulation (药品注册管理办法), issued as State Administration for Market Regulation Order No. 27 and in force since 1 July 2020. It replaced the older "new drug" vs "imported drug" split with a single, class-based system: a drug is registered by what it is, not by where it was made. A foreign-made biological product is now assessed to the same standard as a domestic one.

The three things every registration must prove

Everything in the regulation funnels into three requirements, stated plainly in the law: a drug may be registered only when the applicant shows it is safe, effective and of controllable quality. The application is the evidence for those three claims.

RequirementWhat it meansProved by
SafetyThe product does not cause unacceptable harmPharmacology and toxicology studies, and clinical trials where required
EfficacyThe product does what it claimsClinical trials (phases I–IV) or bioequivalence, depending on class
Quality controlEvery batch meets a defined standardPharmaceutical studies, a validated process, and a defined quality standard

How drugs are classified

The regulation registers drugs under three broad categories, each with its own sub-classes:

Traditional Chinese medicine
Innovative, improved-new, classical-formula, and same-name-same-formula preparations.
Chemical drugs
Innovative, improved-new, and generic drugs.
Biological products
Innovative biological products, improved-new biological products, and already-marketed biological products (including biosimilars).

The biological products category matters here, because every plasma-derived medicine — albumin, IVIG, coagulation factors, PCC, fibrinogen, immunoglobulins — is a biological product. There is no shortcut around the biological-products registration path.

The registration path, end to end

A registration does not start at the submission. It starts years earlier, with the studies. The sequence is fixed:

  1. Pharmaceutical research. Establish the manufacturing process and the quality control of the product.
  2. Pharmacology and toxicology studies. Build the pre-clinical safety picture.
  3. Clinical trials. Phases I–III to show safety and efficacy (bioequivalence for some generics), or a waiver where the regulation allows.
  4. Marketing authorisation application. Submit the dossier to the NMPA Center for Drug Evaluation (CDE).
  5. Formal review. The CDE checks the dossier is complete and accepts it.
  6. Technical review. The CDE evaluates safety, efficacy and quality, and may run a registration inspection and testing.
  7. Approval. The NMPA issues the drug registration certificate with the approved process, quality standard, label and instructions.

Three accelerated channels exist for products that qualify — breakthrough therapy, conditional approval, and priority review — plus a special approval channel. They shorten review time, not the underlying data requirement.

Why biological products are the heavier lift

A plasma-derived product is not a molecule you can fully characterise. It is a complex mixture derived from human plasma, which means the registration data has to cover things a chemical dossier does not: the source plasma and donor screening, the viral inactivation and removal steps, and lot-to-lot consistency across a biological manufacturing process.

That is why the biological-products registration class exists as its own path, and why buyers should read an approval number as evidence that this specific biological product cleared that specific, stricter bar. It is also why the batch release obligation sits on top of registration — a registered biological product still must have every lot released by the state before it can be sold.

What the holder carries after approval

Approval is not the end of the obligations. The marketing authorisation holder is responsible for the product for its whole life, and the registration runs on a five-year renewal cycle. Post-approval changes are managed by risk:

Change typeProcedureExample
Major changeSupplementary application, approved before implementationTransfer of the marketing authorisation
Moderate changeFile with the provincial authority before implementationChange to packaging and labelling
Minor changeReport in the annual reportMinor manufacturing changes

A registration certificate is proof that a product passed a specific, class-based review. It is not proof that a given batch exists, or that a given counterparty may export it. Those live in the rest of the file.

Frequently asked questions

What are the basic requirements to register a drug in China?

An applicant must submit pharmaceutical, pharmacological-toxicological and, where required, clinical trial data that together prove the product is safe, effective and of controllable quality, then pass NMPA review, inspection and testing. On approval, the applicant becomes the marketing authorisation holder and receives a drug registration certificate.

How are drugs classified for registration?

Under the 2020 Drug Registration Regulation, drugs are registered by category: traditional Chinese medicine, chemical drugs and biological products. Biological products are further split into innovative, improved-new and already-marketed (including biosimilars).

Is a biological product registered differently from a chemical drug?

Yes. Biological products — including plasma-derived medicines — follow the biological-products registration class and face stricter pharmaceutical, safety and often clinical requirements. The path is not interchangeable with a chemical drug's path.

Does a foreign drug need a local holder to register?

Yes, in practice. A foreign applicant registers through a local marketing authorisation holder or licensed agent that can hold the registration and respond to the NMPA. The holder is the legal entity named on the approval number.

How long is a registration valid?

A Chinese drug registration runs five years and must be renewed. After approval, the holder still has to meet batch release and GMP obligations, and each lot of a plasma product must be state-released before sale.

What happens after approval?

The holder receives a drug registration certificate with the approved manufacturing process, quality standard, label and instructions. Post-approval changes are classified as approval, filing or report changes, each with its own procedure.

Where to go next

Regulatory support

Registering a biological product is a long road.

We hold the export mandate for already-registered plasma-derived products — talk to us about the registered portfolio instead of starting a new registration from zero.